Trial · NCT02819414
Paracetamol Treatment of the Borderline Significant PDA
NCT02819414, Phase 2, Unknown, Shaare Zedek Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Paracetamol Treatment of the Borderline Significant PDA. Trials, record NCT02819414. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02819414
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Paracetamol Treatment of the Borderline Significant PDA
- NCT number
- NCT02819414
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Shaare Zedek Medical Center
- Conditions
- Patent Ductus Arteriosus
- Interventions
- Paracetamol drops, Placebo
- First posted
- 2016-06-30
- Last updated
- 2016-07-06
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite outcome of death or severe morbidity chronic lung disease [CLD] | Day of life 3 until 40 weeks post-conception | Chronic lung disease will be assessed by time on supplemental oxygen and assisted ventilation. |
| Secondary | Subsequently diagnosed hs PDA | Completion of study intervention until 40 weeks post-conception | Will be assessed by subsequent need for medical or surgical intervention for closure of PDA |
| Secondary | Subsequent incidence of necrotizing enterocolitis (NEC) and/or retinopathy of prematurity (ROP) | Completion of study intervention until 40 weeks post-conception | Study infants will be followed clinically and any occurrence of NEC or ROP will be recorded with its level of significance (Bell staging for NEC and Stage of ROP) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02819414
GET https://conductscience.org/api/trials/v1/NCT02819414/registered